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Phase II Study of Carboplatin, Irinotecan, and Thalidomide
in Patients with Advanced Non-small Cell Lung Cancer
Antonius A. Miller, MD,* Doug Case, PhD,* James N. Atkins, MD,† Jeffrey K. Giguere, MD,‡
and James D. Bearden, MD§
Background:We hypothesized that thalidomide would improve the
response and toxicity profile of chemotherapy with carboplatin and
irinotecan.
Methods: The key eligibility criteria were stage IIIB (malignant
pleural effusion) and IV non–small cell lung cancer, measurable
disease, no prior chemotherapy, prior radiation only for brain me-
tastasis, performance status 0 or 1, and adequate hematologic,
hepatic, and renal function. Treatment consisted of carboplatin at a
calculated area under the curve of 5 and infused intravenously for 30
min on day 1 and irinotecan (50 mg/m2 intravenously for 90 min on
days 1 and 8 every 21 days). Thalidomide was given orally every
evening starting on day 1 until progressive disease; the starting dose
was 200 mg per day, which was escalated by 100 mg per week if
tolerated (maximum 1000 mg per day). The objectives were to
determine the response rate, time to progression, overall survival,
and toxicity profile.
Results: In all, 46 patients were enrolled, but three who never
received protocol treatment were excluded from the analysis. The
characteristics of the 43 eligible and treated patients included me-
dian age 63 (47–79), female/male 13/30, black/white 3/40, PS 0/1 in
10/33, and stage 3/4 in 6/37. The objective response rates were
complete response 1 (2%), partial response 5 (12%), stable disease
24 (56%), progressive disease 9 (21%), and unevaluable for re-
sponse 4 (9%). The median time to progression was 3.7 months
(95% confidence interval [CI], 2.5–4.9). The median survival time
was 8.1 months (95% CI, 5.0–12.9). Frequent toxicities were neu-
tropenia, fatigue/malaise, and nausea/vomiting. Diarrhea was un-
common and mild.
Conclusions: This treatment regimen of carboplatin, irinotecan, and
thalidomide was tolerable, with reversible neutropenia as the major
toxicity and only minor diarrhea. The overall response rate did not meet
our predetermined level of efficacy to merit further investigation.
Key Words: Phase II, Carboplatin, Irinotecan, Thalidomide, Non-
small cell lung cancer.
(J Thorac Oncol. 2006;1: 832–836)
Lung cancer is the leading cause of cancer deaths in bothmales and females in the United States.1 Approximately
15 to 20% of the patients have small cell lung cancer (SCLC),
and 80 to 85% have non–small cell lung cancer (NSCLC).2
Most patients present with stage III or IV disease. In the
treatment of advanced NSCLC, survival is improved by
chemotherapy compared with best supportive care, but the
survival benefit is modest, and no particular two-drug com-
bination is superior. For instance, the Eastern Cooperative
Oncology Group (ECOG) compared cisplatin/gemcitabine,
cisplatin/docetaxel, and carboplatin/paclitaxel against a ref-
erence regimen of cisplatin/paclitaxel in a large randomized
phase III trial, and none of the newer doublets showed
significant improvement in the median survival, which was
approximately 8 months.3
Irinotecan has emerged as another active agent in ad-
vanced NSCLC.4 It is thought to have nonoverlapping toxic-
ities with other drugs (i.e., carboplatin and paclitaxel).5 In a
phase I study of irinotecan and carboplatin in previously
untreated solid tumors that included advanced lung cancer,
dose-limiting diarrhea, leukopenia/neutropenia, and thrombo-
cytopenia were observed at carboplatin area under the curve
(AUC) of 5 on day 1 and irinotecan 60 mg/m2 on days 1, 8,
and 15.6 The recommended phase II doses were carboplatin
AUC of 5 and irinotecan 50 mg/m2.6 In a phase II study of the
combination of carboplatin AUC of 5 and irinotecan 50
mg/m2 days 1, 8, and 15, 36 patients with measurable ad-
vanced NSCLC were treated.7 The results included a re-
sponse rate of 25% (95% confidence interval [CI], 12–42%),
a median survival of 10.8 months, and a 1-year survival rate
of 38.9%, with major toxicities consisting of neutropenia,
thrombocytopenia, anemia, nausea/vomiting, and diarrhea.7
Irinotecan was not given on days 8 or 15 if the leukocyte
count was 3,000/l or if the platelet count was 100,000/
l, or if diarrhea of at least grade 1 was present. The actual
doses of irinotecan relative to the projected doses on days 8
and 15 were noted as 0.86 and 0.43, respectively.7 Because
fewer than half of the patients could receive the dose of
irinotecan on day 15 of the 28-day cycle, the authors sug-
gested that the treatment schedule should be revised.7 This
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led us to investigate a 21-day cycle of carboplatin at an AUC
of 5 on day 1 and irinotecan 50 mg/m2 on days 1 and 8.
Thalidomide has diverse effects that include antiangio-
genic, antineoplastic, and antiinflammatory actions. It is thought
to inhibit angiogenesis by interfering with basic fibroblast
growth factor and vascular endothelial growth factor.8–11 Tha-
lidomide also inhibits tumor necrosis factor-alpha production,
which may result in diminished cancer cachexia.12,13 In a pilot
study assessing the safety of thalidomide in combination with
standard doses of paclitaxel and carboplatin in patients with
advanced NSCLC, nine patients received paclitaxel 225 mg/m2
for 3 hours and carboplatin AUC of 6 with thalidomide at a
starting dose of 200 mg per day.14 The thalidomide dose was
escalated by 200 mg per week to a target dose of 1000 mg per
day if tolerated; thalidomide could continue for up to 6 months.
The most frequent side effects were fatigue, constipation, nau-
sea, myalgia, sensory neuropathy, and myelosuppression. Six-
teen of 17 episodes of grade 3 or 4 hematologic toxicity occurred
in five patients who had received prior chemotherapy. In previ-
ously untreated patients, the drug combination was well toler-
ated. The median tolerated dose of thalidomide was 600 mg per
day. One patient with stage IIIA disease had a partial response,
and one patient with stage IV disease had stable disease for more
than 187 days.14
Irinotecan causes diarrhea and thalidomide causes con-
stipation. Govindarajan et al. observed a striking absence of
gastrointestinal side effects, especially diarrhea and nausea,
when irinotecan and thalidomide were combined.15 The patho-
physiological basis for this observation is unclear, but tumor
necrosis factor-alpha inhibition by thalidomide may be impli-
cated in this effect. Thalidomide also has known immunothera-
peutic properties against inflammatory bowel disease.16
Our hypothesis was that thalidomide might improve the
response and toxicity profile of carboplatin/irinotecan for
three reasons: a) thalidomide has a novel mechanism of
action that is different from classic cytotoxic drugs,8 b) it has
already been successfully combined with carboplatin/pacli-
taxel with promising results in advanced NSCLC,14 and c) it
has been observed that thalidomide decreases the gastroin-
testinal side effects of irinotecan.15 This phase II study
investigated the combination of carboplatin, irinotecan, and
thalidomide with the following objectives: a) to assess the
response rate (primary objective), b) to estimate the time to
progression and the overall survival duration, and c) to
evaluate the toxicity profile.
PATIENTS AND METHODS
Patient Eligibility
All patients had histologically or cytologically docu-
mented NSCLC with either stage IIIB (because of malignant
pleural effusion) or stage IV disease. All patients had to have
measurable disease according to the Response Evaluation
Criteria in Solid Tumors (RECIST) by the National Cancer
Institute. The eligibility criteria included age 18 years,
Eastern Cooperative Oncology Group (ECOG) performance
status 0 or 1, no prior chemotherapy, and no prior radiation
except for brain metastasis. The required laboratory values at
entry were absolute neutrophil count (ANC) 1,500/l,
platelet count 100,000/l, serum creatinine 1.5 mg/dl,
total bilirubin 1.5 mg/dl, and pregnancy test negative for
women of childbearing potential. Females who were pregnant
or nursing were not eligible. Each patient had to give written
informed consent after being informed of the research nature
of the study and had to agree to use approved methods of
birth control (i.e., two methods of birth control for women,
and condoms for men).
Treatment Plan
Carboplatin was dosed at a calculated AUC of 5 and
infused intravenously for 30 minutes on day 1. Irinotecan at
a dose of 50 mg/m2 was infused intravenously for 90 minutes
on days 1 and 8. One cycle of chemotherapy with carboplatin/
irinotecan was 21 days in length, and up to six cycles were
administered. Premedication with ondansetron, granisetron,
or palonosetron in combination with dexamethasone was
standard. Ancillary medications were atropine for acute diar-
rhea from irinotecan and loperamide for delayed diarrhea.
Thalidomide was given orally every evening from day 1 until
disease progression. The starting dose was 200 mg. The
thalidomide dose was escalated by 100 mg every week as
tolerated to a maximum dose of 1000 mg. Thalidomide was
continued until progressive disease was observed. The pro-
longed use of thalidomide was based on the assumption by
Folkman that the antiangiogenic effect is slower than the
cytotoxic effect of chemotherapy.17 Because thalidomide can
cause severe birth defects in humans, women of childbearing
potential were informed of the risks and agreed not to become
pregnant while taking thalidomide. They were instructed to
use effective contraception methods during their participation
in the study. Patients who initially presented with brain
metastases were allowed to receive whole-brain irradiation,
but they had to be neurologically stable and off steroids
before entering this trial. Patients who subsequently devel-
oped brain metastases were considered to have progressive
disease. Palliative radiation therapy to other sites was not
permitted. Patients with disease progression after a minimum
of two cycles of carboplatin and irinotecan and patients with
unacceptable toxicity were removed from protocol treatment.
After patients were removed from this protocol, radiotherapy
and second-line chemotherapy were allowed.
On day 1 of subsequent cycles, treatment was held for
ANC1,500/l or platelets100,000/l. If febrile neutropenia
(defined as temperature 38.3°C or 100.5°F concomitant with
an ANC 500/l), neutropenic sepsis, or a platelet nadir of
25,000/l developed in a given cycle, all subsequent cycles
were given using 75% of carboplatin and irinotecan. If febrile
neutropenia or platelet nadir 25,000/l occurred despite this
dose reduction, then 50% was given in the next and all subse-
quent cycles. If febrile neutropenia or platelet nadir25,000/l
occurred on a subsequent cycle despite this second dose reduc-
tion, protocol therapy was discontinued. The use of granulocyte
colony-stimulating factor or granulocyte-macrophage colony-
stimulating factor was discouraged but allowed if adverse prog-
nostic factors existed.18 On day 8 of a treatment cycle, 100% of
the irinotecan dose was given in cases of ANC 1,500/l and
platelets 100,000/l, and 75% was given in cases of ANC
1,000 to 1,499/l or platelets 75,000 to 99,999/l. In cases of
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ANC1000/l or platelets75,000/l on day 8, treatment was
held and restarted on day 1 of the following cycle at 100% if
counts recovered to ANC1,500/l and platelets100,000/l.
If treatment had to be held for longer than 3 weeks, the patient
was removed from the protocol. For grade 3 nonhematological
toxicities, treatment was held until toxicity had improved to
grade 1 or less, and treatment was continued at 75% dosage
except for hepatic or neurotoxicity, in which cases it was
continued at 50%. For grade 4 nonhematological toxicities,
treatment was held until toxicity improved to grade 1 or less, and
treatment was continued at 50% dosage except for hepatic or
neurotoxicity, in which cases treatment was discontinued.
Clinical Evaluation
Prior to enrollment in the study and before each treat-
ment cycle, patients had a comprehensive history and phys-
ical examination (including performance status), complete
blood counts and differential, and serum chemistries (elec-
trolytes, liver and kidney functions). Albumin, thyroid-stim-
ulating hormone, lactate dehydrogenase, and pregnancy tests
were performed before treatment and as indicated. Blood
counts were repeated weekly. Staging studies included chest
x-ray, CT of the chest and abdomen, bone scan, and CT or
MRI of the brain. Restaging was performed every two cycles
on carboplatin/irinotecan and then at least every 3 months
until documentation of tumor progression while on thalido-
mide. The NCI RECIST criteria were used,19 and the NCI
Common Toxicity Criteria (version 2.0) were in effect when
this trial was activated.
Statistical Analyses
The optimal minimax two-stage phase II design pro-
posed by Simon20 was used to test the null hypothesis that the
objective response was 25% versus the alternative hypoth-
esis that the response rate was40% with type I and II errors
of 10%. The study was prospectively designed to initially
accrue 39 evaluable patients. If nine or fewer of the first 39
evaluable patients responded to therapy, the study was to be
terminated and the null hypothesis “accepted.” However, if
10 or more responded, an additional 25 patients were to be
accrued. It was expected that up to 10% of all patients would
be ineligible or unevaluable; therefore, the overall study size
was expected to be at least 43 and up to 70 patients. The
response rate was estimated by dividing the number of
complete and partial responses by the number of eligible
treated patients. CIs were calculated based on the exact
binomial distribution. Progression-free survival was defined
as the time from protocol registration until disease progres-
sion or death. Survival was defined as the time from regis-
tration until death or the last date of contact. Kaplan–Meier
methods were used to estimate the time to progression and
survival distributions.
RESULTS
Forty-six patients were accrued in the study between
November 2001 and September 2004. Three patients did not
receive any protocol therapy and have been excluded from
the analysis. The characteristics of the 43 eligible treated
patients are shown in Table 1.
At least two cycles of carboplatin and irinotecan were
administered in 39 patients. The median number of cycles
was four. Sixteen patients received all six cycles of carbo-
platin and irinotecan. One patient is alive without tumor
progression at 30 months, and three patients are alive with
progressive disease. The median dose of thalidomide was 400
mg daily (range, 200–800 mg). One patient was able to
tolerate 600 mg of thalidomide daily for 30 months. Table 2
summarizes the response to treatment. Two patients died
within 30 days of registration of their progressive lung
cancer. Two other patients refused further therapy after one
cycle of treatment and thus could not be evaluated for tumor
response. Based on all 43 eligible treated patients, the objec-
tive response rate was 14% (95% CI, 5–28%).
Thalidomide was given until tumor progression. The
median time to progression was 3.7 months (95% CI, 2.5–4.9
months). Thirty-nine of the 43 patients have died. The median
survival time was 8.1 months (95% CI, 5.0–12.9 months).
Progression-free survival and overall survival are graphically
depicted in Figure 1. The estimated 1-year survival rate was 37%.
TABLE 1. Patient characteristics (n  43)
Age
Median (range) 63 (47–79)
60 yr 27 (63%)
Sex
Female 13 (30%)
Male 30 (70%)
Race
Black 3 (7%)
White 40 (93%)
Performance status
0 10 (23%)
1 33 (77%)
Histology
Adenocarcinoma 18
Squamous cell carcinoma 10
Large cell carcinoma 4
Undifferentiated nonsmall carcinoma 11
Stage
IIIB 6 (14%)
IV 37 (86%)
Prior treatment
Chemotherapy 0 (0%)
Radiotherapy 5 (12%)
TABLE 2. Objective response in 43 patients
Complete response 1 (2%)
Partial response 5 (12%)
Stable disease 24 (56%)
Progressive disease 9 (21%)
Early death (within 30 days of registration) 2 (5%)
Unevaluable (patient refusal) 2 (5%)
Overall response rate 6 (14%)
95% confidence interval 5–28%
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Table 3 summarizes the adverse events experienced by
the 43 patients treated on protocol. The most common tox-
icity was reversible neutropenia. Although grade 3 and 4
neutropenia occurred in 16 patients (37%), neutropenic fever
was only observed in one patient (2%). Thrombocytopenia
was also encountered (Table 3) but did not require platelet
transfusion. Diarrhea was not a serious problem. No cases of
uncontrolled hypertension or serious hemorrhage such as
hemoptysis were observed. No grade 5 adverse events were
encountered.
DISCUSSION
This study was prospectively designed with a primary
objective of distinguishing between objective response rates
of 25 versus 40% as stated in the statistical section. When 39
patients could be evaluated for tumor response but only six
responded (Table 2), the study was closed as planned. Our
conclusions are that this treatment regimen of carboplatin,
irinotecan, and thalidomide was tolerable, with reversible
neutropenia as the major toxicity. Diarrhea was an infrequent
toxicity, which was consistent with the hypothesis that tha-
lidomide would counteract the diarrhea from irinotecan.
However, the overall response rate did not meet our prede-
termined level of efficacy to merit further investigation.
In the large phase III study by ECOG, the response rate
for all 1155 eligible patients was 19%, with a median survival
of 7.9 months (95% CI, 7.3–8.5 months).3 These results may
be used as a benchmark for platinum-based doublets with
paclitaxel, docetaxel, or gemcitabine. Our much smaller
phase II trial of carboplatin, irinotecan, and thalidomide
resulted in a response rate of only 14%, yet the median
survival was 8.1 months (95% CI, 5.0–12.9 months). Thus,
we were unable to demonstrate an improvement with the
addition of thalidomide to carboplatin and irinotecan. This
does not preclude the possibility of benefit from adding
thalidomide to a different regimen of chemotherapy. Our
failure to show a benefit for thalidomide also does not
invalidate antiangiogenesis as a valid treatment strategy for
lung cancer.
Antiangiogenic monoclonal antibodies have recently
been developed for the treatment of NSCLC as reviewed by
Sandler.21 Indeed, 878 patients with stage IIIB (pleural or
pericardial effusion) and stage IV nonsquamous NSCLC with
a performance status of 0 or 1 were enrolled by ECOG
contemporary to our trial (July 2001 to April 2004) to a
randomized phase III trial of carboplatin/paclitaxel with and
without bevacizumab.22 Carboplatin/paclitaxel/bevacizumab
had a response rate of 27%, which was significantly
(p  0.0001) higher than the response rate of 10% for carbo-
platin/paclitaxel. Progression-free and overall survival esti-
mates were also significantly superior for the bevacizumab-
containing regimen: 6.4 versus 4.5 and 12.5 versus 10.2
months, respectively. This ECOG study is one of the very few
examples in which the addition of a new drug to a platinum
FIGURE 1. Progression-free and overall
survival.
TABLE 3. Adverse events of grade 3 and 4 severity with an
incidence of 5%
Grade, n (%)
Type of Event 3 4
Blood/bone marrow
Leukocytes 7 (16) 2 (5)
Neutrophils 11 (26) 5 (12)
Hemoglobin 2 (5) 0 (0)
Platelets 2 (5) 1 (2)
Gastrointestinal
Diarrhea 2 (5) 1 (2)
Nausea 5 (12) 0 (0)
Vomiting 5 (12) 0 (0)
Constitutional
Malaise/fatigue 7 (16) 1 (2)
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doublet improved response rate and survival time in patients
with NSCLC.
Bevacizumab adds complexity to the treatment regimen
compared with an oral drug such as thalidomide. On the other
hand, a neurotoxic drug such as thalidomide may have prob-
lems with adherence compared with a parenteral drug like
bevacizumab. Bevacizumab is not indicated in squamous cell
lung cancer. Therefore, further investigations of drugs with
novel molecular target such as VEGF are warranted.
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